BACKGROUND: This multicenter phase II study investigated temozolomide + irinotecan (TEMIRI) treatment in children with relapsed or refractory medulloblastoma. METHODS: Patients received temozolomide 100-125 mg/m(2)/day (days 1-5) and irinotecan 10 mg/m(2)/day (days 1-5 and 8-12) every 3 weeks. The primary endpoint was tumor response within the first 4 cycles confirmed ≥4 weeks and assessed by an external response review committee (ERRC). In a 2-stage Optimum Simon design, ≥6 responses in the first 15 evaluable patients were required within the first 4 cycles for continued enrollment; a total of 19 responses from the first 46 evaluable patients was considered successful. RESULTS: Sixty-six patients were treated. Seven responses were recorded during stage 1 and 15 in the first 46 ERRC evaluated patients (2 complete responses and 13 partial responses). The objective response rate during the first 4 cycles was 32.6% (95% confidence interval [CI], 19.5%-48.0%). Median duration of response was 27.0 weeks (7.7-44.1 wk). In 63 patients evaluated by local investigators, the objective response rate was 33.3% (95% CI, 22.0%-46.3%), and 68.3% (95% CI, 55.3%-79.4%) experienced clinical benefit. Median survival was 16.7 months (95% CI, 13.3-19.8). The most common grade 3 treatment-related nonhematologic adverse event was diarrhea (7.6%). Grade 3/4 treatment-related hematologic adverse events included neutropenia (16.7%), thrombocytopenia (12.1%), anemia (9.1%), and lymphopenia (9%). CONCLUSIONS: The planned study primary endpoint was not met. However, its tolerability makes TEMIRI a suitable candidate chemotherapy backbone for molecularly targeted agents in future trials in this setting.
BACKGROUND: This multicenter phase II study investigated temozolomide + irinotecan (TEMIRI) treatment in children with relapsed or refractory medulloblastoma. METHODS:Patients received temozolomide 100-125 mg/m(2)/day (days 1-5) and irinotecan 10 mg/m(2)/day (days 1-5 and 8-12) every 3 weeks. The primary endpoint was tumor response within the first 4 cycles confirmed ≥4 weeks and assessed by an external response review committee (ERRC). In a 2-stage Optimum Simon design, ≥6 responses in the first 15 evaluable patients were required within the first 4 cycles for continued enrollment; a total of 19 responses from the first 46 evaluable patients was considered successful. RESULTS: Sixty-six patients were treated. Seven responses were recorded during stage 1 and 15 in the first 46 ERRC evaluated patients (2 complete responses and 13 partial responses). The objective response rate during the first 4 cycles was 32.6% (95% confidence interval [CI], 19.5%-48.0%). Median duration of response was 27.0 weeks (7.7-44.1 wk). In 63 patients evaluated by local investigators, the objective response rate was 33.3% (95% CI, 22.0%-46.3%), and 68.3% (95% CI, 55.3%-79.4%) experienced clinical benefit. Median survival was 16.7 months (95% CI, 13.3-19.8). The most common grade 3 treatment-related nonhematologic adverse event was diarrhea (7.6%). Grade 3/4 treatment-related hematologic adverse events included neutropenia (16.7%), thrombocytopenia (12.1%), anemia (9.1%), and lymphopenia (9%). CONCLUSIONS: The planned study primary endpoint was not met. However, its tolerability makes TEMIRI a suitable candidate chemotherapy backbone for molecularly targeted agents in future trials in this setting.
Authors: David A Reardon; Jennifer A Quinn; Jeremy N Rich; Annick Desjardins; James Vredenburgh; Sridharan Gururangan; Sith Sathornsumetee; Michael Badruddoja; Roger McLendon; James Provenzale; James E Herndon; Jeannette M Dowell; Jill L Burkart; Herbert B Newton; Allan H Friedman; Henry S Friedman Journal: Cancer Date: 2005-10-01 Impact factor: 6.860
Authors: D Valteau-Couanet; B Fillipini; E Benhamou; J Grill; C Kalifa; D Couanet; J L Habrand; O Hartmann Journal: Bone Marrow Transplant Date: 2005-12 Impact factor: 5.483
Authors: C Lynn Cheng; Stewart P Johnson; Stephen T Keir; Jennifer A Quinn; Francis Ali-Osman; Csaba Szabo; Hongshan Li; Andrew L Salzman; M Eileen Dolan; Paul Modrich; Darell D Bigner; Henry S Friedman Journal: Mol Cancer Ther Date: 2005-09 Impact factor: 6.261
Authors: Adam J Esbenshade; Mehmet Kocak; Linda Hershon; Pierre Rousseau; Jean-Claude Decarie; Susan Shaw; Peter Burger; Henry S Friedman; Amar Gajjar; Albert Moghrabi Journal: Pediatr Blood Cancer Date: 2016-12-21 Impact factor: 3.167
Authors: Teresa de Rojas; Francisco Bautista; Miguel Flores; Lucía Igual; Raquel Rubio; Eduardo Bardón; Lucía Navarro; Laura Murillo; Raquel Hladun; Adela Cañete; Miguel Garcia-Ariza; Carmen Garrido; Ana Fernández-Teijeiro; Eduardo Quiroga; Carlota Calvo; Anna Llort; Inmaculada de Prada; Luis Madero; Ofelia Cruz; Lucas Moreno Journal: J Neurooncol Date: 2017-12-16 Impact factor: 4.130
Authors: Adam S Levy; Mark Krailo; Susan Chi; Doojduen Villaluna; Linda Springer; Chris Williams-Hughes; Maryam Fouladi; Amar Gajjar Journal: Pediatr Blood Cancer Date: 2021-04-12 Impact factor: 3.838
Authors: Didier Frappaz; Marc Barritault; Laure Montané; Florence Laigle-Donadey; Olivier Chinot; Emilie Le Rhun; Alice Bonneville-Levard; Andreas F Hottinger; David Meyronnet; Anne-Sophie Bidaux; Gwenaële Garin; David Pérol Journal: Neuro Oncol Date: 2021-11-02 Impact factor: 13.029